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ABSTRACT
Objectives: The aim of this study was to determine the prevalence of liver fibrosis in 
patients with human immunodeficiency virus (HIV) monoinfection versus those with HIV 
hepatitis-B virus (HBV) co-infection as assessed with shear wave elastography (SWE) 
in a tertiary sub-Saharan Africa hospital. Materials and Methods: A total of 105 
consecutive patients, 70 with HIV monoinfection and 35 with HIV-HBV co-infection, 
had liver elastography obtained using SWE to assess for the presence of liver fibrosis 
the cutoff of which was 5.6 kPa. Assessment of aspartate aminotransferase-to-platelet 
ratio index (APRI) score (a noninvasive serum biomarker of liver fibrosis) in these 
patients was also done. Results: The prevalence of liver fibrosis was significantly higher 
(P < 0.0001) in patients with HIV-HBV co-infection, 25.7%, compared to those with HIV 
monoinfection, 7.1%. APRI score was greater in patients with HIV-HBV co-infection 
than those with HIV monoinfection. HIV co-infection with HBV accelerates progression 
to liver fibrosis. Association of a low cluster of differentiation 4 (CD-4) count with 
advanced fibrosis supports earlier starting of antiretroviral therapy to prevent rapid 
progression of liver disease in HIV-positive patients. Conclusion: In view of the high 
prevalence of liver fibrosis in patients with HIV-HBV co-infection, regular monitoring 
of the disease progression is recommended.
Key words: Human immunodeficiency virus, Hepatitis-B, liver fibrosis, shear wave 
elastography
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INTRODUCTION
Liver disease in the last decade has become one of the 
leading causes of morbidity and mortality in human 
immunodeficiency virus (HIV) infected individuals with 
chronic liver disease emerging as the leading cause of 
nonacquired immunodeficiency disease syndrome‑related 
deaths in this population.[1] Chronic hepatitis‑B virus (HBV) 
infection in patients with HIV occurs at a rate ten times 
higher than in the general population and is associated 
with increased rate of progression to chronic liver disease.[2]
Management of chronic liver disease is dependent on the 
grade of liver fibrosis to ascertain the urgency and choice 
of treatment and advice on further screening for cirrhosis 
and hepatocellular carcinoma. Though liver biopsy has 
traditionally been the gold standard for diagnosis and staging 
of liver fibrosis, the procedure has paramount shortfalls as a 
medical screening test. It lacks the safety profile, accuracy, 
and accessibility of a standard medical screening test. As a 
result, screening for liver fibrosis in patients with HIV is low. 
The low prevalence of liver disease staging in these patients 
probably contributes to their poor outcome.
In response to the lack of an ideal screening tool for liver 
fibrosis, there has been a quest to develop noninvasive 
methods for diagnosing fibrosis and cirrhosis in the 
last decade. In this respect, there has been significant 
development of special blood parameters and 
elastography. Serum biomarkers, such as aspartate 
aminotransferase (AST)‑to‑platelet ratio index (APRI) 
score and elastography are validated tools for assessment 
of liver fibrosis.[3,4] These noninvasive methods have 
several advantages over liver biopsy including lack of 
adverse effects, reduced sampling error, objectivity in the 
interpretation of results, and appropriateness for repeated 
examinations, all at a lower cost.[5]
Elastography has already been approved by most European 
countries as an evaluation tool for liver fibrosis in patients 
with viral hepatitis.[6]
In Africa, information on liver disease in HIV beyond liver 
enzyme measurements have not been studied.[7] Though 
the burden of HIV‑HBV co‑infection is known to be higher 
in sub‑Saharan Africa as compared to the West, there is a 
paucity of data regarding its effect on chronic liver disease 
in this group of patients.[8]
The aim of this study was to determine the prevalence 
of liver fibrosis in patients with HIV monoinfection as 
compared to those with HIV‑HBV co‑infection using shear 
wave elastography (SWE) at a Tertiary Teaching Hospital 
in Kenya.
MATERIALS AND METHODS
This was a cross‑sectional study at a tertiary hospital. The 
study obtained approval from the institution’s research 
and ethics committee and written informed consent 
was obtained from all participants before enrollment in 
this study. Inclusion criteria were HIV‑positive patients 
attending the HIV clinic at the tertiary hospital who 
consented to the study and had HBV and hepatitis‑C 
virus (HCV) tests. Patients with HIV‑HCV co‑infection, 
massive ascites, those unable to hold their breath for 
adequate elastography readings, and those <18 years of 
age were excluded. The acquisition time for the machine 
used in this study is typically on the order of 100 ms 
which means none‑overt breathing does not affect 
the readings. The technique also detects significant 
motion with no measurement recorded when there is a 
significant motion during the acquisition. One patient 
was excluded based on inability to acquire adequate 
readings.
Between August 2013 and January 2014, 105 patients were 
enrolled in the study. The HIV and HBV infections were 
determined using enzyme immunoassay. Chronic HBV 
infection was determined by a positive hepatitis‑B surface 
antigen for more than 6 months. Based on these tests, two 
groups of patients were identified: Seventy patients with 
HIV monoinfection and thirty five patients with HIV‑HBV 
co‑infection [Figure 1].
Each group had real‑time SWE of the liver performed at the 
radiology department of the hospital. Only one machine, 
Phillips iU22 xMATRIX, was used for the liver elastography 
using a 5 MHz curvilinear probe. The liver elastography was 
carried out by one of two consultant radiologists in the 
radiology department with ultrasonography experience 
of 19 years and 7 years, respectively, a senior resident in 
the radiology department with 3 years’ experience or by 
a sonographer who has over two decades of experience. 
They underwent 3 weeks training on performance of 
elastography which was carried out by a specialist. 
Figure 1: Flow chart showing process of recruitment of patients.
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Real‑time SWE has been shown to have high intra‑observer 
and inter observer reproducibility between an expert 
operator and a novice operator.[9,10]
The persons performing the scans were blind to the 
liver function tests of the patients. All liver stiffness 
measurements (LSMs) were acquired with the patient 
lying supine. In each patient and at the same session, 
10 LSMs were acquired from the right lobe of the liver 
through an intercostal space with the probe in the region 
of the midclavicular line. The SWE box was placed at 
least 2.0 cm from the liver capsule. The area of the SWE 
box was 1 cm2 and was the same for all patients. Prior 
to starting the measurements, patients were trained on 
breath‑hold to reduce erroneous readings resulting from 
inspiration. Each LSM acquisition took approximately 
5 s. The acquisition was from an area free of large vessels 
[Figure 2a and b]. This technique reduces the effects of 
reverberation artifacts arising from the liver capsule and 
pulsations from large vessels on the measurements which 
could lead to erroneously high elastography readings. 
The median value of ten consecutive measurements in 
kilopascals (kPa) was used for statistical analyses.
The measurements obtained were automatically stored in 
the department’s picture archiving and communication 
systems and also recorded in a data sheet. The data 
were then classified into two with elastography scores 
<5.6 kPa classified as having no significant fibrosis and 
scores ≥5.6 kPa representing the presence of fibrosis. 
Elastographic reference ranges have been developed for 
distinguishing presence or absence of fibrosis and the 
presence of cirrhosis using histology as the reference 
standard.[11‑13] Based on these studies, the following 
cutoffs have been recommended for elastographic 
scores in liver fibrosis using SWE: On average, 5.6 kPa 
represents the upper limit for normal, 7.1 kPa the cutoff 
for significant fibrosis, while 12 kPa is the cutoff for the 
presence of cirrhosis.
Calculation of the APRI score was done using the 
most current AST and platelet count available for the 
patient. These were within 3 months of the elastography 
measurement. For patients with more than one set of 
laboratory test results available, the set of results closest 
to the time of the elastography were used. These data were 
obtained from a computerized medical register. The score 
was then calculated using Wai’s formula:[3]
AST upper itof normalforAST
Plateletcount L
/ lim
/
( ) ×
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109
Based on their APRI score, patients were placed into one 
of three classes as follows ‑ Class 1: <0.5, Class 2: 0.51–1.5, 
and Class 3: >1.5.
Statistical analysis
Study data were captured in a spreadsheet  (Excel, 
Microsoft Corporation). The analysis was done using STATA 
version 11.2 StataCorp, Texas, USA.
The continuous metric data obtained from APRI and SWE 
converted to categorical ordinal data using standard 
cut‑offs as explained in the methods above.
Differences in baseline characteristics between patients 
with and without liver fibrosis by SWE were assessed 
using Chi‑square or Fisher’s exact tests, as indicated, 
for categorical data and Wilcoxon rank‑sum tests for 
continuous data.
Prevalence of liver fibrosis as assessed by SWE was 
calculated by dividing the number of patients with liver 
fibrosis based on SWE cutoff score with the total number 
of patients who had undergone the test.
Association between risk factors such as a low cluster of 
differentiation 4 (CD4), cell count (below 200 cells/mm3), 
detectable HIV viral load (HIV viral load > 40 copies/mL), and 
obesity, with liver fibrosis, were assessed by stratification 
and summary odds ratios presented using Mantel‑Haenszel 
method. Those found to have a significant effect were 
subjected to multivariable logistic regression to control 
for the confounding. Pearson’s correlation coefficient was 
used to assess for correlation between SWE and APRI score.
Differences and associations were considered statistically 
significant if the P value was <0.05.
RESULTS
Baseline characteristics
A total of 105 participants were consecutively enrolled; 70 
with HIV monoinfection and 35 with HIV‑HBV co‑infection. 
All patients were on highly active antiretroviral therapy. The 
Figure 2:  43-year-old male with human immunodeficiency virus 
monoinfection (a) Grayscale liver ultrasound image shows acquisition of liver 
stiffness measurement using shear wave elastography. The sample box (arrow) 
is away from the liver capsule and large blood vessels. (b) A table shows 
summary of ten liver stiffness measurement readings of the same patient with 
a median elastography score (encircled) of 2.75 kPa.
a b
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baseline characteristics of the two groups are provided in 
Table 1. 59% were male, and this was not statistically different 
between the two groups. The median age was also similar in 
the two groups. The body mass index (BMI) was statistically 
lower in patients with HIV‑HBV co‑infection (P < 0.02).
The median AST and alanine aminotransferase (ALT) 
were significantly higher in the HIV‑HBV co‑infected 
group (P = 0.001 and P = 0.002, respectively).
At the time of enrollment, the participants had a median 
CD4 count of 418  cells per μL  (IQR 256–569). This 
was comparable for the two groups. The majority of 
patients (72%) had undetectable HIV viral load which was 
not significantly different in the two groups (P = 0.318). 
HBV viral load was undetectable in 68% of the patients 
with HIV‑HBV co‑infection.
The median elastography score was significantly higher in 
the HIV‑HBV co‑infected group (P < 0.001). Figure 3a and b 
show SWE measurement for one of the patients with HIV‑HBV 
co‑infection who had liver fibrosis as per the median score 
of 6.35 kPa.
Prevalence of liver fibrosis
Overall, the prevalence of liver fibrosis based on an SWE 
score >5.6 kPa was 13.3%. The prevalence was significantly 
higher (P < 0.0001) in HIV‑HBV co‑infected patients (25.7%) 
than in the HIV‑monoinfected patients (7.1%) as shown in 
the bar graph in Figure 4.
Risk factors for liver fibrosis
In multivariate analysis, HBV co‑infection, low CD4 
count (<200 cells/mm3), and detectable viral load was 
found to have a significant association with the presence 
of advanced liver fibrosis.
HBV co‑infection was associated with 4.5 times increased 
risk of having significant fibrosis (CI: 1.3–15.4, P = 0.0086).
Although AST, ALT, and BMI were statistically different in 
the two groups, they were not found to have a significant 
association with liver fibrosis. There was no statistically 
significant difference in current alcohol intake between 
the two groups and this was not found to have a significant 
association with the presence of liver fibrosis.
Aspartate aminotransferase‑to‑platelet ratio 
index score
APRI score was significantly higher in patients with 
HIV‑HBV co‑infection compared to those with HIV 
monoinfection (P = 0.0068) as shown in the bar graph in 
Figure 5. Exactly, 33.4% of the co‑infected patients had an APRI 
score of >0.5 compared to 8.6% in the monoinfected group.
The Pearson’s correlation coefficient between APRI score 
and median elastography score was 0.33 (P = 0.0026) 
representing moderate correlation. A scatter plot between the 
two [Figure 6] showed strong positive correlation for patients 
with an APRI score <1. After fitting a linear regression line, for 
every unit increase in APRI score, there is a 0.64 (CI = 0.23–1.06) 
increase in the median elastography score.
DISCUSSION
This study reveals a significantly higher prevalence of liver 
fibrosis in patients with HIV‑HBV co‑infection compared 
to those with HIV monoinfection as assessed by SWE. HBV 
co‑infection was associated with 4.5 times increase in 
the prevalence of liver fibrosis. This suggests a significant 
impact of HBV infection on the progress of liver disease with 
its potential associated morbidity and mortality in patients 
with HIV as has been observed in the data collection on 
adverse events of anti‑HIV drugs study.[14] HIV co‑infection 
with HBV accelerates progression to significant liver fibrosis 
which is in keeping with the higher prevalence of liver 
fibrosis observed in the HIV‑HBV co‑infected group in our 
study.[15,16]
Table 1: Baseline characteristics
Characteristic HIV monoinfection (n=70) HIV‑HBV co‑infection (n=35) P
Median age (years, IQR) 43.5 (38-50) 48 (41-55) 0.0839
Age >40 years, n (%) 45 (64) 28 (80) 0.119
Male sex, n (%) 38 (54.3) 24 (68.6) 0.161
BMI (kg/m2, IQR) 22.8 (20.6-25.8) 21.1 (18.8-22.7) 0.0188
BMI ≥25 kg/m2, n (%) 21 (30) 4 (11) 0.051
Current alcohol intake, n (%) 28 (40) 19 (54) 0.165
Median AST, IU (IQR) 24 (20-31) 34 (25-70) 0.001
Median ALT, IU (IQR) 23.5 (18-28) 32 (23-40) 0.002
Platelet count, mean 266 246 0.307
Median CD4 count (cells/mm3, IQR) 426 (312-595) 398 (102-569) 0.169
CD4 count <200 cells/mm3, n (%) 11 (16) 13 (37) 0.025
HIV viral load category, n (%)
Undetectable (<40 copies/mL) 54 (77) 23 (66) 0.318
Detectable (≥40 copies/mL) 16 (23) 12 (34) 0.246
IQR: Interquartile range, BMI: Body mass index, AST: Aspartate aminotransferase, ALT: Alanine aminotransferase, HIV: Human immunodeficiency virus, HBV: Hepatitis B virus
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Prior to this study, evaluation of liver disease in patients with 
HIV at our institution was limited to liver enzyme studies. 
These tests are however poor markers of liver fibrosis, 
especially in HIV‑infected persons as a significant liver fibrosis 
may be present in individuals with normal transaminases.[17] 
As a result, there may have been underestimation of the 
significance of HIV and HBV on liver disease. Though liver 
biopsy is traditionally the gold standard for the evaluation of 
liver fibrosis, it is not a practical diagnostic tool in this cohort 
of patients. Liver elastography offers a noninvasive means 
of assessment of liver fibrosis, especially in such patients. 
The examination is quick, painless, and highly acceptable to 
patients with results obtained almost instantly. It has been 
widely validated as a noninvasive means for evaluation of 
liver fibrosis.[6]
To our knowledge, only two other studies in Africa, in 
Uganda and Nigeria, have assessed liver fibrosis in HIV 
patients using elastography.[18,19] Both used transient 
elastography as opposed to real‑time SWE used in this study. 
The prevalence of significant liver fibrosis in patients with 
HIV monoinfection was higher in the Ugandan study (17%) 
compared to the Nigerian study (4.7%). Our study found a 
prevalence of 7.1% which is slightly higher than that in the 
Nigerian study. A study using APRI score found a prevalence 
of 8.3% in HIV ‑ monoinfected patients.[20]
The 25.7% prevalence of liver fibrosis in patients with 
HIV‑HBV co‑infection was comparable to the 22.5% found 
in the Nigerian study. The average age of subjects was 
slightly higher in our study. The median age in our study 
was 45 years compared to 34 years for the Nigerian study. 
The progression of liver fibrosis is strongly dependent on 
age.[21] This is probably related to the higher vulnerability 
to environmental factors, especially oxidative stress and 
the reduction in immune capacity of an individual as they 
age. Although the Nigerian study subjects were ART naive 
while those in the current study were not, studies have 
shown that ART does not cause significant histological 
liver disease and may be protective.[22] The results of our 
study are similar to those of the Nigerian study despite 
the different elastography techniques used SWE has 
been shown to be more accurate and reproducible in the 
assessment of liver fibrosis than TE.[9] Monitoring the effect 
Figure 4: Bar graph comparing prevalence of liver fibrosis in the human 
immunodeficiency virus- monoinfected and human immunodeficiency virus 
hepatitis-B virus co-infected patients show a higher prevalence in the co-infected 
group of approximately 26%.
Figure 5: Bar graph shows distribution of aspartate aminotransferase-to-platelet 
ratio index score in the human immunodeficiency -virus monoinfected and 
human immunodeficiency virus hepatitis-B virus co-infected groups and 
indicates that only the co-infected group had patients with an aspartate 
aminotransferase-to-platelet ratio index score above 1.5.
Figure 6: A scatter plot between median elastography scores and aspartate 
aminotransferase-to-platelet ratio index scores with a fitted linear regression 
line. There was a better correlation between the two for patients with aspartate 
aminotransferase-to-platelet ratio index score less than 0.5 as opposed to 
those with higher scores.
Figure 3: A 39-year-old male with the human immunodeficiency virus hepatitis-B 
virus co-infection (a) Grayscale ultrasound image of the liver shows a shear 
wave elastography acquisition box (arrow) with a high elastography score of 
7.4 kPa. (b) A table showing ten liver stiffness measurements readings for the 
same patient with a high median elastography score of 6.35 kPa (encircled).
a b
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of therapy is one the major challenges in the management 
of chronic liver diseases. In a study involving patients 
with chronic hepatitis‑B infection, there was a significant 
decrease in liver elastography measurements compared to 
the baseline 1 year posttreatment with entecavir.[23] Liver 
elastography, being noninvasive, would thus be useful for 
monitoring of liver fibrosis in patients on management for 
chronic liver disease.
This study was not powered to assess the effect of potential 
confounders such as age, alcohol use, CD4 count, and viral 
load on the presence of liver fibrosis. However, low CD4 
count and detectable HIV viral load were associated with 
the presence of liver fibrosis in our study. Other studies have 
shown both to be associated with a significant increase in 
the risk of having advanced liver fibrosis.[19,24] These findings 
are as a result of the worse clinical progression of liver fibrosis 
observed in patients with deeper immunosuppression. This 
would support starting of ART earlier so as to prevent rapid 
progression of liver disease in HIV‑positive patients.
Although the co‑infected group had a significantly lower 
BMI, this was not found to have a significant effect on 
the stage of liver fibrosis following multivariate analysis. 
Furthermore, weight loss has been postulated to result in 
a reduction in abnormal liver enzyme and improvement 
in liver fibrosis.[25]
The co‑infected group had significantly higher APRI scores 
compared to the monoinfected patients as a result of 
higher AST levels in this group. This is in keeping with a 
higher prevalence of advanced liver fibrosis observed in the 
co‑infected patients using SWE. These findings are similar 
to those observed by Post et al., in which HIV patients with 
viral co‑infection (HCV or HBV) had higher APRI scores 
compared to the monoinfected patients.[26] Although HIV 
is associated with thrombocytopenia, high APRI score in 
this referenced study was attributed to elevated AST and 
not low platelets. AST was normal in the monoinfected 
patients in our study, which would explain the lower APRI 
scores in this group. Although most patients with HIV 
may have normal transaminases despite advanced liver 
fibrosis, a high APRI score (which is in essence as a result 
of high AST) is associated with increased mortality in these 
patients.[26] A comparison between the APRI score and 
the median liver elastography scores showed a moderate 
correlation between the two with a stronger correlation for 
patients with a low APRI score. APRI score is a more readily 
available screening tool than SWE as it only requires AST 
and platelet count and would, therefore, be very useful in 
resource ‑poor settings. The poor correlation in patients 
with higher APRI score is likely due to the small number of 
patients with significant fibrosis as assessed by SWE and 
APRI scores and the fact that this study was not powered 
to assess for this correlation.
Limitations
Our study had some limitations. First, the elastographic and 
APRI score findings in the current study were not compared 
to liver biopsy due to technical and ethical challenges. The 
SWE cut‑offs used in the study were based on studies done 
mainly in Europe with most of the subjects having HCV. 
Though there is no reason to believe that the cut‑offs would 
be different in the African population, a study to validate 
the cut‑offs in African population by comparing SWE with 
histology is recommended. Second, the study did not take 
into consideration the effect of other potential causes of 
liver fibrosis which may be unique to sub‑Saharan Africa, for 
example, tropical schistosomiasis and exposure to aflatoxins. 
It is however important to state that the study population 
was not from an area where these two are endemic in Kenya. 
Although the cut‑off of 5.6 kPa is based on the highest 
sensitivity and specificity for detecting fibrosis, there is 
the inherent risk of misclassifying some patients with high 
normal as having fibrosis. The liver elastography scans were 
performed by only one radiologist per patient. Although 
internal quality evaluation of the technique revealed a high 
intra‑ and inter‑observer reproducibility between the two 
radiologists of over 90%, lack of two reviewers per patient 
in this study is a limitation. SWE also has inherent limitations 
with falsely elevated scores seen in patients with acute 
hepatitis, cholestasis, and congestive cardiac disease in 
the absence of fibrosis which were not controlled for in our 
study. Compared to magnetic resonance MR elastography, 
SWE has shown moderate correlation and similar diagnostic 
performance in the diagnosis of hepatic fibrosis of METAVIR 
stage F2 or greater.[27]
CONCLUSION
Given the higher prevalence of liver fibrosis in patients 
with HIV‑HBV co‑infection compared to those with HIV 
monoinfection, the authors recommend routine monitoring 
of this group of patients to check for progression to 
cirrhosis. Significant reduction in LSM has been shown to 
correlate well with response to therapy and since SWE is 
noninvasive, it would form an excellent monitoring tool.
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